Trial Profile
A 12-week, dose-ranging, double-blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of APD356 in obese patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2019
Price :
$35
*
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Arena Pharmaceuticals; Eisai Inc
- 08 Dec 2008 Results have been published in the December 4, 2008 issue of Obesity as reported in a Arena Pharmaceuticals media release.
- 11 Dec 2005 New trial record.